Èȵã¾Û½¹2016Å·ÖÞÐÄË¥Äê»áÁÁµãÔË

ExTraMATCH¢òÑо¿ÏÔʾ£ºÐÄË¥»¼ÕßÔ˶¯»ñÒæÏÔÖø

×î½üµÄÅ·ÃÀºÍÖйúµÄÐÄË¥Ö¸ÄϾù¼º½«ÐÄÔ࿵¸´ºÍÔ˶¯ÑµÁ·ÁÐΪÐÄ˥ȫ³Ì¹ÜÀíµÄÖØÒªÄÚÈÝ¡£È»¶ø£¬ÖÚ¶à¼ÈÍùÑо¿¾ùÉÐδÄÜÇå³þ²ûÃ÷һЩ¹Ø¼üµÄÎÊÌ⣬Ö÷ÒªÓÐÒÔÏÂ3Ï£¨1£©Ô˶¯ÑµÁ·ÄÜ·ñÓ°ÏìÐÄË¥»¼ÕßµÄÁÙ´²½á¾ÖÓÈÆäÊÇËÀÍö¡¢ÒòÐÄ˥סԺ¡££¨2£©Ô˶¯ÑµÁ·¶ÔÐÄË¥²»Í¬ÑÇ×éÈËȺ£¨ÄêÁä¡¢ÐÔ±ð¡¢ÐÄË¥²¡Òò¡¢NYHAÐŦÄÜ·Ö¼¶¡¢LVEFºÍÐÄÀíÒÖÓôÆÀ·Ö£©µÄÓÐÒæÓ°ÏìÊÇ·ñÍêȫһÖ¡££¨3£©Ê²Ã´ÑùµÄÔ˶¯ÑµÁ·Ç¿¶ÈºÍ·½Ê½²ÅÄÜʹÐÄË¥»¼Õß»ñÒæ£¬²¢¿É¸ÄÉÆÉÏÊöµÄÁÙ´²½á¾Ö¡£ºÁÎÞÒÉÎÊ£¬ÕýÈ·»Ø´ðÕâЩÎÊÌâºÜ¹Ø¼ü£¬Î´À´¸üºÃµØÊµÊ©ÐÄË¥»¼ÕßÔ˶¯ÑµÁ·±ØÐëÒÔ´ËΪ»ù´¡¡£ExTraMATCH¢òÊÔÑéÓɴ˶øÉè¼Æ²¢ÊµÊ©¡£

¸ÃÑо¿ÊÇÒ»ÏîÜöÝÍ·ÖÎö£¬¹²ÄÉÈë20ÏîËæ»ú¶ÔÕÕÑо¿¡¢ÀýÐÄË¥»¼ÕßÊý¾Ý¡£ÄÉÈëµÄÊÔÑéÖУ¬ÐÄË¥»¼Õß½ÓÊÜ¡Ý3ÖÜÔ˶¯ÑµÁ·»ò²»Ô˶¯£¬Ëæ·Ã¡Ý6¸öÔ¡£Ñо¿Ê¹ÓøöÌ岡ÀýÊý¾Ý£¨individualpatientdata£¬IPD£©Meta·ÖÎö·½·¨½øÐÐÑо¿·ÖÎö¡£×÷ÕßÓëµ¥¸öÑо¿µÄÑо¿ÕßÁªÏµ»ñµÃÎÄÏ×ԭʼÊý¾Ý£¬ÊÕ¼¯Ã¿¸öÊÔÑéµÄ¸öÌ岡ÀýÊý¾Ý£¬ÓÃԭʼ»¼ÕßÊý¾ÝÖØÐ»ã×Ü·ÖÎö£¬µÃµ½ÖÊÁ¿¸ü¸ß¸ü׼ȷµÄ½á¹û£¨Ò»°ãmeta·ÖÎöÊÇ»ã×ܸ÷¸öÑо¿µÄ½á¹û¶ø²»Êǵ¥¸ö»¼ÕßÊý¾Ý£©¡£¸ßÖÊÁ¿IPDmeta·ÖÎö±»ÈÏΪÊÇÒ½ÁƸÉÔ¤´ëʩЧ¹ûϵͳÆÀ¼ÛµÄ½ð±ê×¼¡£

ExTraMATCH¢òÑо¿½á¹ûÃ÷È·Ö¸³öÓë²»Ô˶¯µÄÐÄË¥»¼ÕßÏà±È£¬Ô˶¯ÕßÈ«ÒòËÀÍö·çÏÕ½µµÍ18%£¬×¡Ôº·çÏÕ½µµÍ11%£¬ÄêÁä¡¢ÐÔ±ð¡¢ÐÄË¥ÑÏÖØ³Ì¶ÈµÈ²»Í¬ÑÇ×éÈËȺ¾ùÒ»Ö»ñÒæ¡£

ExTraMATCH¢òÊÔÑéÑо¿½á¹ûÃ÷È·Ö§³ÖÁ˼¸ºõËùÓеÄÐÄË¥»¼ÕßÔ˶¯ÑµÁ·ÖµµÃÍÆ¼ö¡£¶øÇÒ£¬ÕâÑù×ö×ÜÌåÉÏÊǰ²È«µÄ¡£¿ÉÒÔ´òÏûҽʦ¡¢»¼ÕߺͼÒÈË¿ªÕ¹Ô˶¯ÑµÁ·µÄÖî¶à¹Ë¼É£¬ÓÐÖúÓÚÒ½ÁƺÍÒ½±£Ö÷¹Ü²¿ÃÅÀí½âÐÄË¥µÄÔ˶¯ÑµÁ·£¬²¢ÌṩÏàÓ¦ºÍ±ØÒªµÄÖ§³Ö¡£

ÄϾ©Ò½Ôº»Æ¾þ½ÌÊÚÔÚ½â¶Á¸ÃÑо¿Ê±Ö¸³ö£¬ÎÒÃǵÄÐÄË¥Ô˶¯ÑµÁ·¹¤×÷ÕýÔÚÆð²½£¬½øÒ»²½Íƶ¯Æä·¢Õ¹ÕýÆäʱҲ¡£×÷ΪÁÙ´²Ò½Ê¦£¬ÎÒÃÇÓ¦¹ÄÀø²¡ÇéÎȶ¨ÐÄË¥»¼ÕßÊ×ÏÈ¿ÉÔö¼ÓÈÕ³£ÌåÁ¦»î¶¯£¬²½ÐÐÊÇ×î¼Ñ·½Ê½£¬Ã¿´Î°ëСʱ£¬Ã¿ÖÜ4-5´Î¡£ËٶȺÍʱ¼äÒÔÂÔ¸ÐÆø´­£¬µ«Ô˶¯ºó²¢²»¸Ðµ½Ã÷ÏÔÆ£ÀÍΪ¶È¡£ÒÔ3¸öÔÂΪһ¸ö½×¶Î£¬Ö𽥺ͻºÂýµØÌáÉýÔ˶¯Á¿¡£»¼ÕßÈÔÓ¦¼á³Ö¹æ·¶µÄÒ©ÎïÖÎÁƺͲμӶ¨ÆÚËæ·Ã¼ì²é¡£Ô˶¯ÑµÁ·Êǰ²È«µÄ£¬µ«ÈÔÓÐÒ»¶¨·çÏÕ£¬È粡ÇéÓб仯£¬Ò½Ôº¾ÍÕï¡£

¸÷µØÕýÔÚ½¨É迵¸´»ùµØ£¬ÅäÖÃÓÐרҵÈËÔ±Ö¸µ¼ºÍÏȽøµÄרÓÃÉ豸£¬ÓнÏΪ³ÉÊìµÄÔ˶¯ÑµÁ··½°¸ºÍ±ØÐèµÄ¼à²âÌõ¼þ£¬¿ÉÒÔ±£Ö¤Ô˶¯ÑµÁ·Ð§¹û¸üºÃ£¬¸üΪ°²È«¿É¿Ø£¬Ó¦³ÉΪÐÄË¥»¼ÕßÔ˶¯ÑµÁ·µÄÓÅÑ¡¡£

ESCÐÄË¥Ö¸ÄÏ£ºÄÜÁ¿´úлÖÎÁƸÄÉÆÐÄË¥ºÏ²¢ÐĽÊÍ´»¼ÕßÔ˶¯ÄÍÁ¿

±¾´ÎÅ·ÖÞÐÄË¥Äê»á·¢²¼µÄ°æESC£¨Å·ÖÞÐÄÔಡѧ»á£©¡¶¼±ÂýÐÔÐÄÁ¦Ë¥½ßÕï¶ÏÓëÖÎÁÆÖ¸ÄÏ¡·Ê״ν«Ðļ¡´úлÀàÒ©ÎïÇúÃÀËûàºÄÉÈëÐÄË¥ºÏ²¢ÐĽÊÍ´µÄÖÎÁƲßÂÔ£¬ÈÏΪ¡°µ±¦ÂÊÜÌå×èÖͼÁ»òÆäÌæ´úÒ©ÎïЧ¹û²»¼Ñʱ¿É¿¼ÂÇʹÓÃÇúÃÀËûົº½âÐĽÊÍ´£¬ÓÐЧÇÒ°²È«¡£ÇÒÏÖÓÐÖ¤¾Ý±íÃ÷£º¶ÔÉäѪ·ÖÊý¼õµÍµÄÐÄË¥»¼Õߣ¬ÇúÃÀËû຿ɸÄÉÆNYHAÐŦÄÜ·Ö¼¶¡¢Ìá¸ßÔ˶¯Ê±¼äºÍ×óÊÒ¹¦¹¦ÄÜ¡£¡±

Ö¸ÄÏÄÉÈëÁËÎÒ¹úÎ÷°²Ò½Ôº¸ßµÇ·å½ÌÊÚ·¢±íÓÚ¡¶HEART¡·ÔÓÖ¾µÄÜöÝÍ·ÖÎö¡£¸Ã·ÖÎö¹²ÄÉÈë17ÏîËæ»ú¶ÔÕÕÑо¿£¬ÀýÐŦÄܲ»È«»¼Õߣ¬ÆäÖÐȱѪÐÔÐÄË¥»¼ÕßÀý£¬ÔÚ±ê×¼ÖÎÁƵĻù´¡ÉÏÁªºÏÇúÃÀËûົò°²Î¿¼ÁÖÎÁÆ¡£½á¹ûÏÔʾÇúÃÀËûຽϰ²Î¿¼Á×é×óÊÒÉäѪ·ÖÊý¾ø¶ÔÖµÏÔÖøÔö¼Ó7.49%£¨ÆäÖÐȱѪÐÔÐÄË¥ÑÇ×éÉäѪ·ÖÊý¾ø¶ÔÖµÏÔÖøÌá¸ß7.37%£©£»×óÊÒÊÕËõÄ©ÆÚÈÝ»ýÏÔÖø½µµÍ10.37ml£¨p0.01£©£¬Å¦Ô¼ÐÄÔಡЭ»áÐŦÄÜ·Ö¼¶¸ÄÉÆ0.41£¨p0.01£©£¬Ô˶¯³ÖÐøÊ±¼äÏÔÖø¸ÄÉÆ30.26Ã루p0.01£©¡£

Ò½ÔºÕŸ£´º½ÌÊÚÖ¸³ö£¬ÇúÃÀËûàºÄܹ»Ìá¸ßÑõÀûÓÃЧÂÊ£¬Ôö¼ÓÐļ¡¶ÔȱÑõµÄÄÍÊÜÐÔ£¬ÁªºÏѪÁ÷¶¯Á¦Ñ§Ò©Îï¿ÉÓÐЧ¿ØÖÆÐĽÊÍ´£¬Îª»¼ÕßÔçÆÚÆô¶¯¿µ¸´¶ÍÁ¶´´ÔìÌõ¼þ¡£ÁíÒ»·½ÃæÇúÃÀËû຿Éͬʱ×÷ÓÃÓÚÐļ¡ºÍ¹Ç÷À¼¡£¬ÓÅ»¯ÄÜÁ¿´úл£¬Ìá¸ßÐÄË¥»¼ÕßÐļ¡ÄÜÁ¿´¢±¸´ï33%£¬ÓëÔ˶¯¿µ¸´ÁªºÏ¿É½øÒ»²½Ìá¸ß»¼ÕßÔ˶¯ÄÍÁ¿£¬¸ÄÉÆÉú»îÖÊÁ¿¡£

²Î¿¼ÎÄÏ×£º

1.DrCianionbehalfoftheExTraMATCHIIresearchteamwillpresenttheabstract¡®Exercisetrainingforchronicheartfailure:anindividualparticipantdatameta-analysis¡¯duringthesessionLateBreakingTrialsIII:Focusontrialupdates£¬registriesandmeta-analyseswhichtakesplaceon23Mayfrom08:30to10:00inroomParis.

2.ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure£¬EuropeanHeartJournalAdvanceAccesspublishedMay20£¬

3.GaoDetal.rimetazidine:ameta-analysisofrandomisedcontrolledtrialsinheartfailure.Heart.;97:

4.MontiLA£¬etal.Metabolicandendothelialeffectsoftrimetazidineonforearmskeletalmuscleinpatientswithtype2diabetesandischemiccardiomyopathy.AmJPhysiolEndocrinolMetab.;:E54¨CE59

5.FragassoG£¬etal.Effectsofmetabolicmodulationbytrimetazidineonleftventricularfunctionandphosphocreatine/adenosinetriphosphateratioinpatientswithheartfailure.EurHeartJ.;27£¨8£©:-8

6.BelardinelliR£¬etal.Trimetazidinepotentiatestheeffectsofexercisetraininginpatientswithischemiccardiomyopathyreferredforcardiacrehabilitation.EurJCardiovascPrevRehabil.;15£¨5£©:-40

ÔÞÉÍ

³¤°´







































最好的白癜风医院电�
北京白癜风的最好医�



×ªÔØÇë×¢Ã÷£ºhttp://www.cdncw.com/xlsjby/7579.html

µ±Ç°Ê±¼ä£º